Diethylpropion HCl is a prescription medication that is primarily used to help people manage weight loss, especially when diet and exercise alone are not enough. It belongs to a class of drugs called appetite suppressants and is usually prescribed for short-term use. Diethylpropion works by helping reduce feelings of hunger and making it easier to stick to a healthier eating plan. It’s most often recommended for adults who are overweight or obese and are at risk for health problems like diabetes, high blood pressure, or heart disease.

Diethylpropion works by affecting the central nervous system, specifically by increasing the activity of certain chemicals in the brain that control appetite. It stimulates the release of neurotransmitters like norepinephrine, which signals your brain to feel less hungry. This can help reduce cravings and support healthier eating habits. Additionally, it may boost energy levels, helping people stay more active throughout the day, which further contributes to weight management.

This medication is not suitable for everyone. People with a history of heart disease, high blood pressure, stroke, or glaucoma should avoid using Diethylpropion unless closely supervised by a doctor. It’s also not recommended for those with a history of substance abuse or certain psychiatric conditions like anxiety or agitation. People currently taking monoamine oxidase inhibitors (MAOIs) or other stimulant medications should not use it. Always talk to your doctor before starting this medication, especially if you have pre-existing health concerns.

Diethylpropion can interact with other medications that affect the nervous system, such as antidepressants, antipsychotics, or other weight-loss drugs. It may also interfere with blood pressure medications or increase the effects of caffeine and other stimulants, leading to a higher risk of heart problems or nervousness. If you are taking prescription drugs or supplements, discuss them with your healthcare provider before using Diethylpropion to avoid unwanted interactions.

Common side effects include dry mouth, restlessness, dizziness, or difficulty sleeping. Less common reactions can include increased heart rate, headaches, or changes in mood like anxiety or irritability. Rare but serious effects include chest pain, severe headaches, or swelling in the hands and feet, which should be reported to a doctor immediately. Because Diethylpropion affects the heart and blood pressure, regular check-ups are recommended during treatment.

Diethylpropion is not recommended during pregnancy or while breastfeeding. There is a risk that the medication could affect the developing baby or interfere with milk production. If you are pregnant, planning to become pregnant, or breastfeeding, it’s important to discuss safer alternatives with your healthcare provider. Maintaining a balanced diet and seeking lifestyle interventions are usually preferred during this time to support both mother and baby’s health.

Store this medication at 68°F to 77°F (20°C to 25°C) and away from heat, moisture and light. Keep all medicine out of the reach of children. Throw away any unused medicine after the beyond use date. Do not flush unused medications or pour down a sink or drain.

1. Abenhaim L, Moride Y, Brenot F, et al. Appetite-suppressant drugs and the risk of primary pulmonary hypertension. N Engl J Med 1996;335:609-16.
2. Tenuate (diethylpropion hydrochloride) package insert. Bridgewater, NJ: Aventis Pharmaceuticals; 2003 Nov.
3. Tenuate® (diethylpropion hydrochloride) package insert. Bridgewater, NJ: Aventis Pharmaceuticals; 2003 Nov.
4. Haller CA, Benowitz NL. Adverse cardiovascular and central nervous system events associated with dietary supplements containing ephedra alkaloids. N Engl J Med 2000;343:1833—8.
5. Karch SB. Ma huang and the Ephedra alkaloids. In: Toxicology and Clinical Pharmacology of Herbal Products, 1st ed. (Cupp MJ ed.) Humana Press. Totowa, New Jersey. 2000, pp. 11—25.
6. White LM, Gardner SF, Gurley BJ, et al. Pharmacokinetics and cardiovascular effects of Ma-huang (Ephedra sinica) in normotensive adults. J Clin Pharmacol 1997;37:116—22.
7. US Food and Drug Administration. Adverse events with Ephedra and other botanical dietary supplements. FDA Medical Bulletin; Sept 1994.
8. Naik SD, Freudenberger RS. Ephedra-associated cardiomyopathy. Ann Pharmacother 2004;38:400—3.
9. Serevent® Diskus (salmeterol xinafoate inhalation powder) package insert. Research Triangle Park, NC: GlaxoSmithKline; 2008 Mar.
10. Strattera® (atomoxetine) package insert. Indianapolis, IN: Eli Lilly and Company; 2008 May.
11. Meridia® (sibutramine) package insert. North Chicago, IL: Abbott Laboratories; 2003 Oct.
12. han JC, Cockram CS, Critchley JA. Drug-induced disorders of glucose metabolism. Mechanisms and management. Drug Saf 1996;15:135—57.
13. Furoxone® (furazolidone) package insert. Eatontown, NJ: Roberts Pharmaceutical Corporation; No date.
14. Zyvox™ (linezolid) package insert. Kalamazoo, MI: Pharmacia & Upjohn Company; 2008 May.
15. Matulane (procarbazine) package insert. Gaithersburg, MD: Sigma-tau Pharmaceuticals, Inc; 2008 Mar.
16. Azilect (rasagiline mesylate) tablets. Kansas City, MO: Teva Neurosciences, Inc.; 2014 May.
17. `Elavil® (amitriptyline) package insert. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2000 Dec.
18. Aventyl® (nortriptyline) package insert. Indianapolis, IN: Eli Lilly and Company; 1998 Aug.
19. Vivactil® (protriptyline) package insert. East Hanover, NJ: Odyssey Pharmaceuticals, Inc.; 2003 Jan.
20. Phendimetrazine tartrate extended-release capsules package insert. Laurelton, NY: Eon Labs Manufacturing, Inc.; 1994 Apr.
21. Bostwick JM, Brown TM. A toxic reaction from combining fluoxetine and phentermine. J Clin Psychopharmacol 1996;16:189—90.
22. Schmeling WT, Warltier DC, McDonald DJ, et al. Prolongation of the QT interval by enflurane, isoflurane, and halothane in humans. Anesth Analg 1991;72:137—44.
23. Kuenszberg E, Loeckinger A, Kleinsasser A, et al. Sevoflurane progressively prolongs the QT interval in unpremedicated female adults. Eur J Anaesthesiol 2000;17:662—4.
24. Enflurane package insert. Buffalo, NY: MINRAD Inc.; 2001 Jan.
25. Ultane® (sevoflurane) package insert. North Chicago, IL: Abbot Laboratories; 2003 Aug.
26. Halothane, USP package insert. North Chicago, IL: Abbott Laboratories; 1998 Mar.
27. Unithroid™ (levothyroxine sodium tablets, USP) package insert. Bohemia, NY: Jerome Stevens Pharmaceuticals, Inc.; 2000 Aug.
28. Levothroid (levothyroxine sodium tablet) package insert. Shenandoah, IA: Lloyd Pharmaceutical; 2011 June.
29. Armour Thyroid® package insert. St. Louis, MO: Forest Pharmaceuticals Inc.; 2002 November.
30. Isovue-M® (iopamidol) package insert. Princeton, NJ: Bracco Diagnostics, Inc.; 2002 Jul.
31. Omnipaque™ (iohexol) package insert. Princeton, NJ: Amersham Health; 2003 Apr.
32. Wellbutrin XL® (bupropion) package insert. Research Triangle Park, NC: GlaxoSmithKline; 2006 June.
33. Cercato C, Roizenblatt VA, Leanca CC, et al. A randomized double-blind placebo-controlled study of the long-term efficacy and safety of diethylpropion in the treatment of obese subjects. Int J Obes (Lond) 2009;33:857-65.
34. O’Keefe JC, Butrous GS, Dymond DS, et al. Ventricular arrhythmias complicating weight reduction therapy in a patient with a prolonged QT interval. Postgrad Med J 1985;61:419-21.